Immunotherapy cocktail aims to turn untreatable stomach tumors into surgical targets

NCT ID NCT07638631

Not yet recruiting Disease control Sponsor: Chen Lizhu Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) can shrink locally advanced stomach cancer that cannot be surgically removed. The goal is to make the tumors small enough for surgery. The study enrolls about 30 adults with PD-L1 positive, unresectable gastric cancer who have not had prior treatment. Researchers will measure how many patients become eligible for surgery and how well the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ipilimumab, sintilimab, and modified XELOX chemotherapy
What this could lead to: If successful, this combination could shrink inoperable stomach tumors enough to allow surgical removal, potentially improving long-term outcomes.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. The combination of immunotherapy and chemotherapy can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED GASTRIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.